Invention Grant
US08951521B2 Compounds having activity of suppressing activation of TGF-β receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus
有权
具有抑制TGF-β的激活活性的化合物 受体，筛选化合物的方法，以及用于预防或治疗由丙型肝炎病毒引起的疾病的组合物
- Patent Title: Compounds having activity of suppressing activation of TGF-β receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus
- Patent Title (中): 具有抑制TGF-β的激活活性的化合物 受体，筛选化合物的方法，以及用于预防或治疗由丙型肝炎病毒引起的疾病的组合物
-
Application No.: US13819979Application Date: 2011-08-30
-
Publication No.: US08951521B2Publication Date: 2015-02-10
- Inventor: Soichi Kojima , Mitsuko Hara , Takehisa Matsumoto , Daisuke Takaya
- Applicant: Soichi Kojima , Mitsuko Hara , Takehisa Matsumoto , Daisuke Takaya
- Applicant Address: JP Saitama
- Assignee: Riken
- Current Assignee: Riken
- Current Assignee Address: JP Saitama
- Agency: Sughrue Mion, PLLC
- Priority: JP2010-192803 20100830
- International Application: PCT/JP2011/069620 WO 20110830
- International Announcement: WO2012/029792 WO 20120308
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C12N9/99 ; C07K16/28 ; C07K16/40 ; C12Q1/37
Abstract:
An object is to provide a compound capable of inhibiting activation of TGF-β receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-β receptor, and this binding results in activation of TGF-β receptors. Moreover, binding sites between the NS3 protease and type I TGF-β receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-β receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-β receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-β receptor or the like as an index.
Public/Granted literature
Information query
